Prot# CLBH589E2301: A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients with Hodgkin's Lymphoma Who Are at Risk For Relapse After High Dose Chemotherapy and Autologous Stem Ce

Project: Research project

Project Details

Effective start/end date5/3/104/30/14


  • Novartis Pharmaceuticals Corporation (CLBH589E2301)